SURGENEX® created SurForce®, an amniotic membrane injectable allograft, using our patent-pending Excellion® Process. SurForce® is a minimally manipulated product regulated under the FDA, which allows Surgenex® to sell approved allograft products with confidence to Healthcare Providers. If you are a Healthcare Provider, please visit Surgenex.com for a detailed overview.
As with any condition or injury, a patient must consult their Primary Care Physician or qualified Healthcare Provider for medical advice. If you feel you are a candidate for SurForce® injections, schedule a visit with your Provider to talk about the potential benefits and outcomes of Amniotic Membrane Allografts.
SurForce® is a cryopreserved injectable derived from Amniotic Membrane Tissue.
For patient outcomes and success stories, please contact the SurForce® Healthcare Provider nearest you. You can also peruse through our patient testimonial section here.
The easiest way to get started is by filling out the contact questionnaire found here. We can identify the nearest SurForce® Providers in your area. A Provider will contact you shortly to address any of your questions or concerns. Surgenex distributes its products exclusively to verified medical facilities.
Our bodies naturally degenerate over time. The regenerative processes that were once vibrant and energetic in our youth become slower and impeded as we age.
Your Provider may or may not recommend post-treatment rehabilitation. This decision will depend heavily upon the injured area and its pathology/etiology, as well as your current physical health status. Patients should work with their Healthcare Provider to determine if rehab will be necessary and/or beneficial.
Depending on the etiology, pathology, and severity of the chief complaint, each patient will be unique. Healthcare Providers can gather subjective and objective information such as patient history, orthopaedic examinations, diagnostic imaging, and lab results to assess and determine the patient’s needs. Based on these findings, Healthcare Providers can specify an appropriate treatment plan. Costs associated with specific procedures may depend on these variables. For specifics, contacting the nearest Provider of SurForce® for a consultation is recommended.
Depending on the affected region, or if there are multiple locations needing an injection, the treatment procedure can be administered during a standard office visit. Specific times may vary depending on factors inherent to the complications of the patient’s needs. The application of the treatment is non-surgical, and requires no pre-treatment preparation time.
There are several advantages to using Amniotic Membrane tissues rather than invasive medical procedures. Unlike pharmaceuticals and lengthy surgical procedures, to date no negative side effects have been reported with amniotic membrane allografts.
As with any treatment modality in Healthcare, there is always an inherent risk. It is understood from research, amniotic membrane is considered immune-evasive, and that no adverse side effects are evident. Furthermore, SurForce® maintains the highest standards of safety in our industry, exceeding the FDA’s minimum safety requirements.
Surgenex uses the Excellion® Process to produce SurForce®. This patent-pending process is a highly manual and surgical process that isolates the amniotic membrane layer of the placenta. No other portion of the placenta is utilized.
Research shows that amniotic membrane tissue allografts contain extracellular matrices including growth factors, anti-fibrotics , anti-microbials, are immune-evasive, and have anti-inflammatory properties.
Research also shows it has the potential to repair articular cartilage. Please peruse our Research section here for research articles related to the incredible benefits of amniotic membrane tissue allografts.
|15 min||1-2 hrs||2-4 hrs|
"Pain is all I knew. It was just kind of natural to go through the day with aches and sharp spikes of discomfort. After just one injection, the chronic pain in my left shoulder was completely gone!"
"I can’t open jars or turn certain doorknobs, which can be quite frustrating. I was recommended by my Physician on this new Amniotic injection treatment. About 2 weeks after receiving these SurForce® injections, I noticed that the pain had subsided, and without thinking, I was using my left hand and wrist more naturally, I literally forgot I had a bad wrist! I also received an injection in my right shoulder the same day and I feel that has been very beneficial. The pain in my shoulder is completely gone! Much thanks to Surgenex for providing such a life changing treatment."
"It didn’t matter what pills I took or what I did to try to find relief with homeopathy or acupuncture. The pain was unbearable, but not now...every morning I wake up and literally say, “Thank you, SURGENEX!"
"They’ve become less and less effective at relieving my symptoms. I decided to try something different and went with the SurForce® injectable form Surgenex. It has been three weeks, and my pain level are down from a 7/10to 1/10, and is getting better each day!At this point, I am very happy I chose to do the SurForce® injection rather than opting for surgery. So far I am very happy I made this decision."
"With traditional therapies such as kinesio taping, physical therapy, etc. I always find it very difficult to walk, climb stairs, or any type of exercise. Since receiving the SurForce® injections on both knees, I can say with certainty that my pain levels have significantly decreased, I can do activities such as walking, traveling, and climbing stairs with no pain! I highly recommend this treatment to anyone suffering from knee pain, as this SurFoce injection will change your life."
"My exercise frequency has all but disappeared, which was vital to the lifestyle I used to live and enjoy. I’m 40 now, and I am determined to stay fit. One year ago I received the MRI report on my knee which revealed severe chondral thinning. I took the advice of my Physician, and In April 2016, I opted for the SurForce® injection. It’s now been four months; I’m amazed at the results. My knee feels great, and I plan to start cross fit in the next two months. Thank you Surgenex for giving me my lifestyle back!"
"I decided to opt for the SurForce®injection of Amniotic membrane. This has been one of the best decisions I've ever made! It was amazing to be able to get off the treatment table and take my first step without severe stabbing pain. I went home and followed all my Physicians recommendations. Not even a month post injection, my pain levels have decreased by 50%, my mobility improves daily, and I'm now back in the gym to rehabilitate my body completely. I'm truly grateful and consider this treatment a blessing! I would recommend this to anyone suffering from chronic debilitating pain!"
"My football career left me with a horrible quality of life that I never thought would change. Then I was introduced to Surgenex... Now my shoulder and knee feel 100% better!"
Amniotic membrane allografts
is shaping the future of healthcare!
Amniotic membrane allograft tissue has been an accepted method of treatment since the early 1900s. The healthcare community has benefited from the tissue regeneration outcomes in specialties such as surgery, orthopedics, pain management, burn care, eye, as well as dental. More recently, Podiatric Physicians have been effectively applying these allografts to patients with diabetic foot ulcers. These treatments are yielding paradigm-shifting outcomes for their patients.
Amniotic membrane tissue injections have been growing in popularity over the past few decades Research and development have increased opportunities and discovered a variety of ground-breaking applications.
Utilizing the latest research and implementing efficient operations, SURGENEX® will focus on innovative research-proven products.
Explore the research and articles below involving the use of amniotic allograft tissue and how it plays an impactful role in the future of regenerative medicine.
Research - Data - Clinical Studies
Discover what the top scientist, researchers and research universities are saying about the future of amniotic membrane products. SurForce® is an injectable flowable Amniotic Membrane Allograft which is used for a wide variety of clinical applications including:
Unsuccessful healing represents a significant medical dilemma for both patients and clinicians and create a financial burden on the health care system. Despite the efforts of physicians, many injuries fail to heal with standard care alone. For decades human amniotic membrane composed of both amnion and chorion has shown remarkable therapeutic potential, but only recent preservation methods have allowed its widespread use. Variations in configurations and the ability to micronize the material allow clinical uses that were previously not possible. Although there are limited data available regarding most amniotic membrane-based products, there is substantial preclinical and clinical evidence supporting the rationale and effectiveness of dHACM allograft as a treatment modality. The rapidly growing body of evidence suggests that the properties inherent in dHACM promote tissue regeneration and healing, recruiting patients' own stem cells into the wounded area. Randomized controlled trials evaluating dHACM now include more than 200 patients collectively and the results consistently show improved healing. Use of dHACM has been shown to be more clinically effective and cost-effective than other frequently used advanced wound care products. This cost-effectiveness results from dHACM showing higher healing rates and more rapid healing than other advanced wound care products. Cost-effectiveness is also enhanced through the availability of grafts of multiple sizes, which reduces wastage, and through ease of handling and storage for clinical use. Ongoing and future studies will further define and establish the value of amniotic membrane for chronic tissue repair and regeneration.
Placenta has a long history of use for treating burns and wounds. It is a rich source of collagen and other extracellular matrix proteins, tissue reparative growth factors, and stem cells, including mesenchymal stem cells (MSCs). Recent data show its therapeutic potential for orthopaedic sports medicine indications.PURPOSE:
To provide orthopaedic surgeons with an anatomic description of the placenta, to characterize its cellular composition, and to review the literature reporting the use of placenta-derived cells and placental tissue allografts for orthopaedic sports medicine indications in animal models and in humans.
STUDY DESIGN: Systematic review.METHODS:
Using a total of 63 keyword combinations, the PubMed and MEDLINE databases were searched for published articles describing the use of placental cells and/or tissue for orthopaedic sports medicine indications. Information was collected on placental tissue type, indications, animal model, study design, treatment regimen, safety, and efficacy outcomes. Results were categorized by indication and subcategorized by animal model.RESULTS:
Outcomes for 29 animal studies and 6 human studies reporting the use of placenta-derived therapeutics were generally positive; however, the placental tissue source, clinical indication, and administration route were highly variable across these studies. Fourteen animal studies described the use of placental tissue for tendon injuries, 13 studies for osteoarthritis or articular cartilage injuries, 3 for ligament injuries, and 1 for synovitis. Both placenta-derived culture-expanded cells (epithelial cells or MSCs) and placental tissue allografts were used in animal studies. In all human studies, commercial placental allografts were used. Five of 6 human studies examined the treatment of foot and ankle pathological conditions, and 1 studied the treatment of knee osteoarthritis.CONCLUSION:
A review of the small number of reported studies revealed a high degree of variability in placental cell types, placental tissue preparation, routes of administration, and treatment regimens, which prohibits making any definitive conclusions. Currently, the clinical use of placenta is limited to only commercial placental tissue allografts, as there are no placenta-derived biological drugs approved for the treatment of orthopaedic sports medicine conditions in the United States. However, this review shows that the application of placental cells or tissue allografts appears to be safe and has potential to improve outcomes for orthopaedic sports medicine indications.
Amniotic membrane (AM) transplantation is increasingly used in ophthalmological and dermatological surgeries to promote re-epithelialization and wound healing. Biologically active cells in the epithelial and stromal layers deliver growth factors and cytokines with anti-inflammatory, anti-bacterial, anti-immunogenic and anti-fibrotic properties. In this work, confocal microscopy was used to show that our cryopreservation protocol for AM yielded viable cells in both the stromal and epithelial layers with favorable post-transplant outcome. AM was obtained from Caesarean-section placenta, processed into allograft pieces of different sizes (3 cm × 3 cm, 5 cm × 5 cm, and 10 cm × 10 cm) and cryopreserved in 10 % dimethyl sulfoxide using non-linear controlled rate freezing. Post-thaw cell viability in the entire piece of AM and in the stromal and epithelial cell layers was assessed using a dual fluorescent nuclear dye and compared to hypothermically stored AM, while surveys from surgical end-users provided information on post-transplant patient outcomes. There was no significant statistical difference in the cell viability in the entire piece, epithelial and stromal layers regardless of the size of allograft piece (p = 0.092, 0.188 and 0.581, respectively), and in the entire piece and stromal layer of hypothermically stored versus cryopreserved AM (p = 0.054 and 0.646, respectively). Surgical end-user feedback (n = 49) indicated that 16.3 % of AM allografts were excellent and 61.2 % were satisfactory. These results support the expanded clinical use of different sizes of cryopreserved AM allografts and address the issue of orientation of the AM during transplant for the treatment of dermatological defects and ocular surface disorders.
Amniotic membrane (AM)-derived products have been successfully used in ophthalmology, plastic surgery, and wound care, but little is known about their potential applications in orthopaedic sports medicine.PURPOSE:
To provide an updated review of the basic science and preclinical and clinical data supporting the use of AM-derived products and to review their current applications in sports medicine.STUDY DESIGN:
A systematic search of the literature was conducted using the Medline, EMBASE, and Cochrane databases. The search term amniotic membrane was used alone and in conjunction with stem cell, orthopaedic, tissue engineering, scaffold, and sports medicine.RESULTS:
The search identified 6870 articles, 80 of which, after screening of the titles and abstracts, were considered relevant to this study. Fifty-five articles described the anatomy, basic science, and nonorthopaedic applications of AM-derived products. Twenty-five articles described preclinical and clinical trials of AM-derived products for orthopaedic sports medicine. Because the level of evidence obtained from this search was not adequate for systematic review or meta-analysis, a current concepts review on the anatomy, physiology, and clinical uses of AM-derived products is presented.CONCLUSION:
Amniotic membranes have many promising applications in sports medicine. They are a source of pluripotent cells, highly organized collagen, antifibrotic and anti-inflammatory cytokines, immunomodulators, and matrix proteins. These properties may make it beneficial when applied as tissue engineering scaffolds, improving tissue organization in healing, and treatment of the arthritic joint. The current body of evidence in sports medicine is heavily biased toward in vitro and animal studies, with little to no human clinical data. Nonetheless, 14 companies or distributors offer commercial AM products. The preparation and formulation of these products alter their biological and mechanical properties, and a thorough understanding of these differences will help guide the use of AM-derived products in sports medicine research.